Cass Sunstein Sees Some Sense in Trump Regulation Policy
(Bloomberg View) -- Very quietly, the Trump administration recently issued a draft of its annual report on the costs and benefits of federal regulations. It's a responsible and highly professional document — and a corrective to the noisiest claims, from both the White House and its critics, on the whole topic of regulation.
The report is required by the Regulatory Right-to-Know Act, enacted in 2000. Since that time, Republican and Democratic administrations have cataloged the costs and benefits of federal regulations. In an era of sharp partisan divisions, there has been a high degree of continuity across administrations in terms of the basic aspiration to careful analysis, free from political interference.
This year's report is especially interesting, because the Trump administration's Office of Information and Regulatory Affairs is cataloging the work of its predecessors — above all, that of the Barack Obama administration. The report's numbers suggest that the benefits of previous regulations far exceeded their costs.
In fiscal year 2016, for example, the anticipated costs of regulations range from $3.3 billion to $4.6 billion — but the anticipated benefits range from $13.6 billion to $27.3 billion. (The range accounts for uncertainty about the precise numbers.) That means that the net benefits are, at a minimum, a whopping $9 billion — $24 billion at a maximum.
The report also offers a 10-year accounting, with eight of those years coming under Obama. The estimated aggregate costs are between $59 billion to $88 billion. The aggregate benefits are much higher than that: between $219 billion to $695 billion.
Not only are the net benefits high, but the numbers also show a degree of discipline on the cost side. A range of $5.9 billion to $8.8 billion per year is far from modest, and it would be great to reduce it, but in comparative terms, it's not unmanageable. For comparison, the annual budget of the Department of Transportation has recently been in the vicinity of 10 times that amount.
At the same time, the report offers some important caveats. First, it emphasizes that for some rules, agencies failed to offer a complete accounting of costs and benefits — and that independent agencies, such as the Federal Reserve and the Securities and Exchange Commission, often fail to monetize benefits and costs at all.
That's not good. The report rightly notes “that for the purposes of informing the public and obtaining a full accounting, it would be highly desirable to obtain better information on the benefits and costs of the rules issued by independent agencies.”
Second, the report observes that the current figures — for quantifying both benefits and costs — depend on assumptions that might turn out not to be true. It strikes just the right note when it states that the report was issued after a change in administration, and that its figures do “not imply an endorsement by the current Administration of all of the assumptions made and analyses conducted at the time these regulations were finalized.”
Third, the report draws attention to uncertainties. One example: It's not easy to turn the protection of homeland security, or of personal privacy, into monetary equivalents.
Another example: Many of the reported benefits come from reducing a single air pollutant: particulate matter. But scientists disagree about the magnitude of those benefits. Some forms of particulate matter may have more serious adverse effects than others. If some forms are significantly less toxic than others, then the benefits of reductions will be lower than currently expected.
In accordance with tradition, the new cost-benefit report offers recommendations for reform. Importantly, the Trump administration embraces the commitment to cost-benefit analysis as “the primary analytical tool to inform specific regulatory choices.” Since that commitment was initially imposed by President Ronald Reagan, it's not exactly a big surprise that a Republican successor would reaffirm it. Nonetheless, it's excellent news.
At least as much as any of its predecessors, the report emphasizes the importance of deregulation, including the elimination of rules that are “outdated, unnecessary, or ineffective,” or that impose “costs that exceed benefits.” It also draws attention to the need to reassess past regulations, with clear emphasis on their actual (as opposed to merely anticipated) effects.
Here, as well, there is a bipartisan consensus. We need far more evidence on the concrete effects of existing regulations — whether they are imposing high costs, whether they can be streamlined, whether they are delivering big benefits.
There's a lot of chest-thumping on regulation, both by those who act as if it's the most serious problem facing the United States today, and by those who have never seen a health or safety regulation they don't like. This week's sober, fair-minded report is a reminder that everything turns on the numbers — and that political dogmas mask all of the serious questions.
This column does not necessarily reflect the opinion of the editorial board or Bloomberg LP and its owners.
Cass R. Sunstein is a Bloomberg View columnist. He is the editor of "Can It Happen Here? Authoritarianism in America" and a co-author of “Nudge: Improving Decisions About Health, Wealth and Happiness.”
Disclosure: I was administrator of the Office of Information and Regulatory Affairs from 2009 to 2012, and helped to oversee regulation and the annual cost-benefit report during those years.
To contact the editor responsible for this story: Katy Roberts at kroberts29@bloomberg.net.
For more columns from Bloomberg View, visit http://www.bloomberg.com/view.
©2018 Bloomberg L.P.
-
The Economic Imperative: Analysing The Material Driving Force Behind India-Canada Strategic Reset
This economic complementarity is further reinforced by deep institutional investment ties and talent mobility, which form the bedrock of the bilateral framework.
-
Medicine Pricing: Where Must Profit Stop?
India must confront excessive margins, hidden incentives and regulatory gaps that threaten the integrity of medicine.
-
Why Amazon And Flipkart Are Struggling To Beat Meesho In India's Smaller Cities
With 274 million users and lowest-cost logistics, Meesho is defending its value commerce crown against giants like Amazon and Flipkart.
-
High US Salaries, No Green Card Certainty: The Financial Calculation Facing Indian H-1B Families
The suspension of PERM processing at eight technology employers does not cancel existing H-1B visas. What it does is force a question many Indian families have been avoiding: is the US salary worth tying your career and family plans to one employer?
-
Swiggy vs Eternal: Food Delivery's Two Rivals Are No Longer In The Same Race
Eternal is building a private AI assistant, dark.ai. Swiggy is still working out how to make Instamart pay, with an operating loss of Rs 895 crore in the July-September quarter while Blinkit stayed profitable.
-
Where You Live Shapes How You Get To Work | The Reason Why
Two-wheelers are the most popular way to get to work in India, accounting for nearly 43% of workplace commutes.
-
Unhedged Position: Can India See An Indonesia-Style Time Correction?
The Nifty is trading below levels it first clocked in 2024. Is there, then, as I have suggested in the headline, potential that the current time correction drags on painfully for the next three-five, even ten years?
-
Navigating Friction And Energy Realities: An Analysis Of Marco Rubio's October Visit To India
Occurring at a critical juncture marked by stalled trade negotiations and escalating geopolitical pressures over global energy supplies, the visit offers a profound window into modern US-India relations.
-
India Exports Capital. Why Not Export Trusteeship?
The big question, then, is whether India can build an institution that global borrowers, investors, banks, and lawyers can trust, even without an Indian connection.
-
France's Economy & Politics Are In Crisis | The Reason Why
Let's look at how the French economy and politics evolved under Nicolas Sarkozy, Franois Hollande and Emmanuel Macron.